Diagnostic imaging using positron emission tomography for gynecological malignancy

Imaging has played a pivotal role in the management of gynecological malignancy. Positron emission tomography (PET), particularly 18F‐fluorodeoxyglucose (18F‐FDG) PET to reflect cellular glycolytic metabolism, is being increasingly used and has proven superior to conventional imaging including ultrasonography, computed tomography (CT), and magnetic resonance imaging. Studies of and evidence for the utility of 18F‐FDG PET/CT for the detection of local or metastatic disease, treatment planning, response assessment, restaging of recurrent disease, and prognostic assessment are growing. We review the latest evidence for and limitations of 18F‐FDG PET/CT in the diagnosis of gynecological malignancy. Moreover, we also describe the benefits of and evidence for other tracers.